Depot-medroxyprogesterone acetate and combined oral contraceptive use and cervical neoplasia among women with oncogenic human papillomavirus infection

American Journal of Obstetrics and Gynecology

Volumn 200, Issue 5, 2009, Pages 489.e1-489.e8

  Harris, Tiffany G ^a   Miller, Leslie ^b   Kulasingam, Shalini L ^d   Feng, Qinghua ^b   Kiviat, Nancy B ^b   Schwartz, Stephen M ^a,c   Koutsky, Laura A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

cervical intraepithelial neoplasia; depot medroxyprogesterone acetate; hormonal contraception; oncogenic human papillomavirus infection

Indexed keywords

MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; VIRUS DNA;

ADULT; ARTICLE; CANCER GRADING; CANCER RISK; CASE CONTROL STUDY; COLPOSCOPY; CORRELATION ANALYSIS; DNA DETERMINATION; DRUG UTILIZATION; FEMALE; HISTOPATHOLOGY; HORMONAL CONTRACEPTION; HUMAN; HUMAN TISSUE; LONG TERM CARE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TUMOR VIRUS; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; VIRUS INFECTION; WART VIRUS;

EID: 64249084991     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2009.01.030     Document Type: Article

References (40)

1. Smith J.S., Green J., Berrington de Gonzalez A., et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 361 (2003) 1159-1167
2. Appleby P., Beral V., Berrington de Gonzalez A., et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 370 (2007) 1609-1621
3. Deacon J.M., Evans C.D., Yule R., et al. Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN3 among those infected: a case-control study nested within the Manchester cohort. Br J Cancer 83 (2000) 1565-1572
4. Green J., Berrington De Gonzalez A., Smith J.S., et al. Human papillomavirus infection and use of oral contraceptives. Br J Cancer 88 (2003) 1713-1720
5. Winer R.L., Lee S.K., Hughes J.P., Adam D.E., Kiviat N.B., and Koutsky L.A. Incident infection with genital human papillomavirus: rates and risk factors in a cohort of college women. Am J Epidemiol 157 (2003) 218-226
6. Moscicki A.B., Hills N., Shiboski S., et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 285 (2001) 2995-3002
7. Giuliano A.R., Papenfuss M., Abrahamsen M., et al. Human papillomavirus infection at the United States-Mexico border: implications for cervical cancer prevention and control. Cancer Epidemiol Biomarkers Prev 10 (2001) 1129-1136
8. Castle P.E., Walker J.L., Schiffman M., and Wheeler C.M. Hormonal contraceptive use, pregnancy and parity, and the risk of cervical intraepithelial neoplasia 3 among oncogenic HPV DNA-positive women with equivocal or mildly abnormal cytology. Int J Cancer 117 (2005) 1007-1012
9. Vaccarella S., Herrero R., Dai M., et al. Reproductive factors, oral contraceptive use, and human papillomavirus infection: pooled analysis of the IARC HPV prevalence surveys. Cancer Epidemiol Biomarkers Prev 15 (2006) 2148-2153
10. Shapiro S., Rosenberg L., Hoffman M., et al. Risk of invasive cancer of the cervix in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen oral contraceptives (South Africa). Cancer Causes Control 14 (2003) 485-495
11. Kulasingam S.L., Hughes J.P., Kiviat N.B., et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 288 (2002) 1749-1757
12. Harris T.G., Kulasingam S.L., Kiviat N.B., et al. Cigarette smoking, oncogenic human papillomavirus, Ki-67 antigen, and cervical intraepithelial neoplasia. Am J Epidemiol 159 (2004) 834-842
13. Baseman J.G., Kulasingam S.L., Harris T.G., et al. Evaluation of primary cervical cancer screening with an oncogenic human papillomavirus DNA test and cervical cytologic findings among women who attended family planning clinics in the United States. Am J Obstet Gynecol 199 (2008) 26.e1-26.e8
14. Gravitt P.E., Peyton C.L., Apple R.J., and Wheeler C.M. Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J Clin Microbiol 36 (1998) 3020-3027
15. The Bethesda System for reporting cervical/vaginal cytologic diagnoses: revised after the second National Cancer Institute Workshop, April 29-30, 1991. Acta Cytol 37 (1993) 115-124
16. Winer R.L., Kiviat N.B., Hughes J.P., et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 191 (2005) 731-738
17. Kruger-Kjaer S., van den Brule A.J., Svare E.I., et al. Different risk factor patterns for high-grade and low-grade intraepithelial lesions on the cervix among HPV-positive and HPV-negative young women. Int J Cancer 76 (1998) 613-619
18. Coker A.L., Sanders L.C., Bond S.M., Gerasimova T., and Pirisi L. Hormonal and barrier methods of contraception, oncogenic human papillomaviruses, and cervical squamous intraepithelial lesion development. J Womens Health Gend Based Med 10 (2001) 441-449
19. Hildesheim A., Herrero R., Castle P.E., et al. HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica. Br J Cancer 84 (2001) 1219-1226
20. Moreno V., Bosch F.X., Munoz N., et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 359 (2002) 1085-1092
21. Castle P.E., Wacholder S., Lorincz A.T., et al. A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women. J Natl Cancer Inst 94 (2002) 1406-1414
22. Konya J., and Dillner J. Immunity to oncogenic human papillomaviruses. Adv Cancer Res 82 (2001) 205-238
23. Whitacre C.C. Sex differences in autoimmune disease. Nat Immunol 2 (2001) 777-780
24. de Villiers E.M. Relationship between steroid hormone contraceptives and HPV, cervical intraepithelial neoplasia and cervical carcinoma. Int J Cancer 103 (2003) 705-708
25. Pater A., Bayatpour M., and Pater M.M. Oncogenic transformation by human papillomavirus type 16 deoxyribonucleic acid in the presence of progesterone or progestins from oral contraceptives. Am J Obstet Gynecol 162 (1990) 1099-1103
26. Yuan F., Auborn K., and James C. Altered growth and viral gene expression in human papillomavirus type 16-containing cancer cell lines treated with progesterone. Cancer Invest 17 (1999) 19-29
27. Mittal R., Tsutsumi K., Pater A., and Pater M.M. Human papillomavirus type 16 expression in cervical keratinocytes: role of progesterone and glucocorticoid hormones. Obstet Gynecol 81 (1993) 5-12
28. von Knebel Doeberitz M., Spitkovsky D., and Ridder R. Interactions between steroid hormones and viral oncogenes in the pathogenesis of cervical cancer. Verh Dtsch Ges Pathol 81 (1997) 233-239
29. von Knebel Doeberitz M., Bauknecht T., Bartsch D., and zur Hausen H. Influence of chromosomal integration on glucocorticoid-regulated transcription of growth-stimulating papillomavirus genes E6 and E7 in cervical carcinoma cells. Proc Natl Acad Sci USA 88 (1991) 1411-1415
30. Valente P.T., Schantz H.D., and Trabal J.F. Cytologic changes in cervical smears associated with prolonged use of depot-medroxyprogesterone acetate. Cancer 84 (1998) 328-334
31. Kiviat N., Koutsky L.A., and Paavonen J. Cervical neoplasia and other STD-related genital tract neoplasias. In: Holmes K.K., Sparling P.F., Mardh P.A., et al. (Eds). Sexually transmitted diseases (1999), McGraw-Hill, New York
32. Volk E.E., Jax J.M., and Kuntzman T.J. Cytologic findings in cervical smears in patients using intramuscular medroxyprogesterone acetate (Depo-Provera) for contraception. Diagn Cytopathol 23 (2000) 161-164
33. Zahm D.M., Nindl I., Greinke C., Hoyer H., and Schneider A. Colposcopic appearance of cervical intraepithelial neoplasia is age dependent. Am J Obstet Gynecol 179 (1998) 1298-1304
34. Miller L., Patton D.L., Meier A., Thwin S.S., Hooton T.M., and Eschenbach D.A. Depomedroxyprogesterone-induced hypoestrogenism and changes in vaginal flora and epithelium. Obstet Gynecol 96 (2000) 431-439
35. Mauck C.K., Callahan M.M., Baker J., et al. The effect of one injection of Depo-Provera on the human vaginal epithelium and cervical ectopy. Contraception 60 (1999) 15-24
36. Kuhn L., Denny L., Pollack A.E., and Wright T.C. Prevalence of visible disruption of cervical epithelium and cervical ectopy in African women using Depo-Provera. Contraception 59 (1999) 363-367
37. Bahamondes L., Trevisan M., Andrade L., et al. The effect upon the human vaginal histology of the long-term use of the injectable contraceptive Depo-Provera. Contraception 62 (2000) 23-27
38. Nischan P., Ebeling K., Thomas D.B., and Hirsch U. Comparison of recalled and validated oral contraceptive histories. Am J Epidemiol 138 (1993) 697-703
39. Manhart L.E., and Koutsky L.A. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia?. A meta-analysis. Sex Transm Dis 29 (2002) 725-735
40. Winer R.L., Hughes J.P., Feng Q., et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 354 (2006) 2645-2654